Mayo bounces back in biotech
Sunday 26 February 2006
Celtic Pharma, based in Bermuda but with offices in London and New York, is the only fund of its kind that focuses on buying drugs rather than companies. The firm trawls cash-starved biotech companies for promising late-stage drugs that it intends to shepherd through clinical development. The firm hopes that once the drugs get to approval it will be ableto sell them to big pharmaceutical groups.
"There is a capital drought in the biotech sector and a pipeline problem in the pharma sector," said Mr Mayo, the joint founder. "We're basically arbitraging those two conditions."
Mr Mayo, a former banker, helped demerge Zeneca from ICI and then moved to Marconi, where he led a disastrous acquisition spree. The other founder is Stephen Evans-Frekes, who sold his biotech company, Sugen, to Pharmacia, now Pfizer, for $720m in 1999.
Celtic expects to close its first $500m fund next month, and then plans to raise $500m in mezzanine funds to bring its available cash to $1bn.
Since June, the company has accumulated a portfolio of eight drugs and plans to acquire up to 20 in total. "Measured in that way, it would make us one of the biggest pharmaceutical companies in the world," said Mr Mayo.
The firm's first drug due for approval is a pain-relieving gel for osteoarthritis sufferers. Celtic says it could replace the $5bn in sales that evaporated after Merck's Vioxx was withdrawn and others in its class, such as Celebrex, were forced to add strong warnings to their labels.
The drug's approval in Switzer- land is expected next year and approval in major markets would come in 2008.
Harry Potter actor suffered 'severe flu-like symptoms' on a flight from London to Orlando
Rap music mogul accused of running two men over in his truck
First full-length look is finally here
The party's potential nominations read like a high school race for student body president
- 2 The awkward moment Sarah Palin raised $25,000 for Hillary Clinton's election campaign
- 3 Ball pool for adults opens in London
- 4 Amal Clooney gives excellent response to fashion question at European Court of Human Rights
- 5 Baldness could soon be treated using stem cells, scientists hope
Woman falls to her death as she celebrates marriage proposal at the edge of Ibiza cliff
Mia Khalifa: Pornhub star claims Drake sent her 'cringeworthy' naked photos on Instagram
Saudi preacher who 'raped and tortured' his five -year-old daughter to death is released after paying 'blood money'
The awkward moment Sarah Palin raised $25,000 for Hillary Clinton's election campaign
Ball pool for adults opens in London
9 reasons Greece's experiment with the radical left is doomed to failure
'We would evict Queen from Buckingham Palace and allocate her council house,' say Greens
Have we reached 'peak food'? Shortages loom as global production rates slow
Greece elections: Syriza and EU on collision course after election win for left-wing party
British grandmother Lindsay Sandiford faces execution by firing squad in Indonesia
Liberal Democrat minister defends comments suggesting immigration causes pub closures
iJobs Money & Business
£30000 - £35000 per annum + Benefits: Ashdown Group: Marketing Manager - Marke...
£13000 per annum: Recruitment Genius: This Pension Specialist was established ...
£23000 - £26000 per annum + Benefits: Ashdown Group: Market Research Executive...
£25000 - £35000 per annum: Recruitment Genius: A Technical Report Writer is re...